Bessemer Group Inc Arcellx, Inc. Transaction History
Bessemer Group Inc
- $61.3 Billion
- Q4 2024
A detailed history of Bessemer Group Inc transactions in Arcellx, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 30 shares of ACLX stock, worth $1,860. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30
Previous 30
-0.0%
Holding current value
$1,860
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ACLX
# of Institutions
224Shares Held
44.7MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$271 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$232 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$218 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$216 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$207 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.72B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...